PET Imaging of Integrin αVβ3 Expression by Beer, Ambros J. et al.





T Th he er ra an no os st ti ic cs s   
2011; 1:48-57 
Review 
PET Imaging of Integrin V3 Expression 
Ambros J. Beer1, Horst Kessler2, Hans-Jürgen Wester3 and Markus Schwaiger1  
1.  Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, Munich, Germany 
2.  Institute for Advanced Study und Center of Integrated Protein Science, Technische Universität München, Department 
Chemie, Garching, Germany 
3.  Chair for Pharmaceutical Radiochemistry, Garching, Germany  
 Corresponding author: Dr. Ambros Beer, Department of Nuclear Medicine, Klinikum rechts der Isar, Ismaningerstr. 22, 
81675 Munich, Germany, Tel.: +49 89 4140 6085; E-mail: ambros.beer@tum.de 
© Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/ 
licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. 
Published: 2011.01.17 
Abstract 
PET imaging of integrin v3 expression has been studied intensely by the academia and recently 
also by the industry. Imaging of integrin v3 expression is of great potential value, as the integrin 
v3 is a key player in tumor metastasis and angiogenesis. Therefore PET imaging of this target 
might be a suitable in-vivo biomarker of angiogenesis and metastatic potential of tumors. In this 
manuscript, the various strategies for PET imaging of the integrin v3 will be summarized, in-
cluding monomeric and multimeric radiolabelled RGD peptides and nanoparticles. While most 
experiments have been performed using preclinical tumor models, more and more clinical results 
on PET imaging of v3 expression are available and will be discussed in detail. However, while a 
multitude of radiotracer strategies have been successfully evaluated for PET imaging of v3, the 
ultimate clinical value of this new imaging biomarker still has to be evaluated in large clinical trials. 
Key words: PET, integrin v3, molecular imaging, angiogenesis, metastasis 
1. INTRODUCTION 
 Integrins  are  heterodimeric  transmembrane 
glycoproteins  consisting  of  different    and 
subunits which play an important role cell-cell- and 
cell-matrix-interactions.  Especially  well  examined  is 
the  integrin  v3  and  its  role  in  angiogenesis  and 
tumor  metastasis  by  facilitating  endothelial  and  tu-
mor  cell  migration.  Angiogenesis  is  a  fundamental 
process involved in a variety of physiological as well 
as  pathological  conditions.  Physiologically,  it  is  re-
quired for development, wound repair, reproduction 
and response to ischemia. Pathologically, it is associ-
ated with disease conditions like arthritis, psoriasis, 
retinopathies and cancer [1]. Since Folkman in 1971 
first articulated the concept that the growth of solid 
tumors remains restricted to 2-3 mm in diameter until 
the onset of angiogenesis, subsequent investigations 
have identified more than 20 angiogenic growth fac-
tors,  their  receptors  and  signal  transduction  path-
ways. Moreover, endogenous angiogenesis inhibitors 
have been discovered and the cellular and molecular 
characterization of the angiogenic phenotype in hu-
man  cancers  has  been  achieved  [2].  The  concept  of 
antiangiogenic therapy has evolved over the last years 
as a therapeutic strategy in clinical oncology aimed at 
stopping  cancer  progression  by  suppressing  the  tu-
mor  blood  supply.  Especially,  the  VEGF  (vascular 
endothelial  growth  factor)  antibody  Avastin®  has 
shown favourable results in combination with stand-
ard cytotoxic chemotherapy in metastasized colorectal 
cancer, breast cancer and non-small cell lung cancer 
[3-4]. This increasing use of targeted therapies leads to 
a  growing  demand  for  imaging  tumor  response  to 
these therapies, as usually only a subset of patients 




antiangiogenetic agents rather lead to a stop of tumor 
progression than to tumor shrinkage, the approach of 
measuring tumor response by a reduction of tumor 
size is not applicable and might take a very long time 
to assess. Therefore, there is great need for imaging 
biomarkers of early tumor response to noncytotoxic 
drugs, which predict subsequent clinical response [5]. 
Such  biomarkers  would  not  only  facilitate  clinical 
trials of new drugs but could also be used to aid in the 
selection of optimal treatment for individual patients 
(“personalized medicine”). Positron emission tomog-
raphy (PET) using tracers for assessment of glucose 
metabolism by [18F]FDG or proliferation by [18F]FLT 
or qualitative assessment of sst-receptor expression by 
[68Ga]DOTATOC  has  already  shown  promising  re-
sults  in  clinical  studies  for  response  assessment  of 
cytotoxic chemotherapies  and peptide receptor radi-
otherapy  [6-7].  In  a  similar  way,  targeting  specific 
molecular markers of angiogenesis by PET imaging 
might be used for response assessment of antiangio-
genic therapies, like the integrin v3. In this chapter 
we  will  discuss  the  different  strategies  currently  in 
use for imaging of integrins with PET. As most pub-
lished results deal with imaging of the integrin v3 
and as this is the only integrin to date successfully 
visualized in patients with PET, we will focus on this 
target.  
2. CHARACTERISTICS OF PET IMAGING 
 PET  imaging  has  the  advantage  of  being  very 
sensitive  to  low  concentrations  of  tracer  molecules 
and  of  having  unlimited  depth  penetration.  PET  is 
approximately  10  times  more  sensitive  than  SPECT 
and is able to detect very low amounts of tracers at the 
picomolar  range.  Moreover,  PET  is  a  quantitative 
imaging  modality  which  is  an  advantage  over  MRI 
and conventional  optical imaging techniques. How-
ever, with the introduction of fluorescence mediated 
tomography  (FMT),  quantitative  measurements  are 
also  possible  with  OI  techniques  [8].  PET  is  well 
suited  to  molecular  imaging  of  angiogenesis  using 
targeted tracers because of the generally low concen-
trations  of  target  molecules.  This  also  facilitates 
translation  of  preclinical  results  and  tracers  to  the 
clinic,  because  toxicity  is  rarely  an  issue  with  PET 
tracers due to the low absolute amount of substance 
used. This is e.g. advantageous compared to classical 
MR contrast agents, where usually substantially larg-
er amounts of substances have to be used. However, 
PET usually can only be performed at facilities that 
have  the  necessary  cyclotron  or  have  a  cyclotron 
nearby for delivery of radiotracers and which the re-
quired radiochemical laboratories for the preparation 
of  the  tracers.  On  the  contrary,  SPECT  imaging  is 
much more widely available than PET imaging and 
the radionuclides used for SPECT are easier to pre-
pare  and  usually  have  a  longer  half-life  than  those 
used for PET (6 hours for [99mTc], 67 hours for [111In], 
and 13.2 hours for [123I]). However, with the increas-
ing use of generator produced positron emitting ra-
dionuclides like [68Ga], this problem might be over-
come in the future for PET as well [9]. Another limi-
tation of PET is the lower spatial resolution compared 
to MRI, CT and US. With current state of the art clin-
ical PET scanners, a resolution of 3-4 mm is possible 
[10]. However, this does not apply to preclinical ani-
mal  scanners,  which  may  allow  for  submillimeter 
resolutions even in small rodents [11]. 
3. PET IMAGING OF INTEGRIN v3 
EXPRESSION 
 In the clinics, the most commonly used way to 
assess vascularisation and angiogenesis is the use of 
functional  imaging,  e.g.  dynamic  contrast  enhanced 
MRI or CT (DCE MRI / DCE CT). While functional 
imaging of hemodynamic parameters of angiogenesis 
can  be  performed  on  routinely  used  MR  and  CT 
scanners, the interpretation of the results with regard 
to their physiological meaning often remains difficult 
[12].  Moreover,  most  of  the  methods  applied  are 
technically challenging and with regard to DCE MRI 
difficult to standardize [13]. Therefore more specific 
markers of angiogenetic activity in tumors are desira-
ble  to  facilitate  assessment  of  angiogenesis  and  re-
sponse  evaluation  during  antiangiogenic  therapy. 
One approach is to identifying molecular markers of 
and to use specific ligands to these targets conjugated 
with positron emitters which allow for PET imaging. 
As mentioned before, one of the most promising and 
best examined targets in this respect is the integrin 
v3, which has been studied extensively as a target 
for molecular imaging preclinically, but also has been 
studied in first clinical studies in the past years [14]. 
Integrins  are  heterodimeric  transmembrane 
glycoproteins  consisting  of  different  -  and 
-subunits which play an important role cell-cell- and 
cell-matrix-interactions  and  tumour  metastasis  by 
facilitating  endothelial  and  tumor  cell  migration.  It 
has  been  found  that  several  extracellular  matrix 
(ECM)  proteins  like  vitronectin,  fibrinogen  and  fi-
bronectin interact with integrins via the amino acid 
sequence arginine-glycine-aspartic acid or RGD in the 
single  letter  code  [15].  Based  on  these  findings, 
monomeric  as  well  as  multimeric  linear  as  well  as 
cyclic  peptides  including  the  RGD  sequence  have 
been  introduced.  The  pentapeptide  cy-




Kessler and co-workers and shows high affinity and 
selectivity for v3 [54]. It has evolved as one of the 
most prominent lead structures for the development 
of molecular imaging compounds for the assessment 
of v3 expression [16, 55]. For the first evaluation of 
this  approach,  radioiodinated  RGD  peptides  have 
been synthesised which showed comparable affinity 
and selectivity to the lead structure. In vivo they re-
vealed receptor-specific tumour uptake but also pre-
dominantly  hepatobiliary  elimination,  resulting  in 
high  activity  concentration  in  liver  and  intestine, 
which is unfavourable for patient studies [17]. Several 
strategies to improve the pharmacokinetics of radio-
halogenated peptides have therefore been developed. 
These  strategies  comprise  conjugation  with  sugar 
moieties, hydrophilic amino acids and polyethylene 
glycol (PEG). The glycosylation approach is based on 
the introduction of sugar derivatives which are con-
jugated  to  the  -amino  function  of  a  corresponding 
lysine  in  the  peptide  sequence.  By  conjugating  the 
RGD  containing  cyclic  pentapeptide  cy-
clo(-Arg-Gly-Asp-DPhe-Val-) with glucose- or galac-
tose-based  sugar  amino  acids,  [*I]Gluco-RGD  and 
[18F]Galacto-RGD have been developed for PET and 
SPECT imaging (Fig. 1). 
 
  
Figure 1: Example of a [
18F]Galacto-RGD microPET scan 
of a nude mouse (A) with a Lewis Lung Cell Cancer (LLC) 
and  a  M21  melanoma  xenograft  (M21).  Corresponding 
immunohistochemistry of αvβ3 expression is shown for the 
LLC in B and for the M21 tumour in C. The LLC tumor 
shows αvβ3 expression on the neovasculature but not on 
the tumor cells, while the M21 tumour shows αvβ3 ex-
pression both on the neovasculature and on the tumor cells. 
Consequently, the PET signal is much more intense in the 
M21 tumour and only moderate in the LLC tumor.  
The glycosylation strategy improved pharmaco-
kinetics  of  these  compounds,  which  showed  pre-
dominantly  renal  tracer  elimination  and  increased 
activity  uptake  and  retention  in  a  murine  tumour 
model  compared  with  the  first  generation  peptides 
[18].  The  conjugation  of  hydrophilic  D-amino  acids 
was  also  used  to  improve  the  pharmacokinetics  of 
peptide-based tracers [19]. Again, tracer elimination 
could  be  shifted  to  the  renal  pathway,  but  tumour 
uptake of the compound [18F]DAsp3-RGD was lower 
than that found for [18F]Galacto-RGD. However, tu-
mour/background  ratios  calculated  from  small  ani-
mal  PET  images  were  comparable  due  to  the  even 
faster elimination. PEGylation is another way to im-
prove many properties of peptides and proteins [20]. 
Chen et al. conjugated RGD-containing peptides with 
PEG moieties with different sizes, using different ra-
diolabelling  strategies.  These  studies  revealed  very 
different  effects  of  PEGylation  on  the  pharmacoki-
netics and tumour uptake and retention of RGD pep-
tides, which seem to depend strongly on the nature of 
the lead structure and perhaps on the size of the PEG 
moiety [21].  
 Extensive  preclinical  evaluations  concerning 
monomeric  compounds  has  been  carried  out  using 
[*I]Gluco-RGD  and  [18F]Galacto-RGD  [22-23].  The 
M21human  melanoma  model  is  well  characterized 
concerning  αvβ3  expression  and  has  been  used  for 
initial  in  vivo  evaluation  [24].  Using  this  model, 
[18F]Galacto-RGD and [125I]Gluco-RGD uptake in the 
tumour 120 min p.i. was 1.5 and 1.8% ID/g, respec-
tively. Blocking experiments injecting 6 mg c(RGDfV) 
per kg mouse 10 min prior to tracer injection reduced 
tumour accumulation to approximately 15% of con-
trol for [125I]Gluco-RGD and to approximately 35% of 
control  for  [18F]Galacto-RGD,  which  demonstrates 
receptor specific accumulation. Furthermore, imaging 
studies  with  mice  bearing  melanoma  tumours  with 
increasing amounts of αvβ3-positive cells (produced 
by mixing M21 and M21-L cells) showed that there is 
a correlation between integrin expression and tracer 
accumulation  [14].  These  data  demonstrate  that 
non-invasive  determination  of  αvβ3  expression  and 
quantification  with  radiolabelled  RGD  peptides  is 
feasible even when using static emission scans. This is 
an important aspect for future clinical use, as static 
emission scanning is easier to perform than dynamic 
scanning  and  moreover  allows  for  whole-body  im-
aging, whereas dynamic imaging is limited to one bed 
position of the scanner. Moreover, animal PET studies 
with increasing amounts of c(RGDfV) were obtained 
that  indicated  that  the  dose-dependent  blocking  of 
tracer uptake in the receptor positive tumour could be 




with the RIPTag model, in order to assess, whether 
serial  imaging  with  radiolabelled  RGD-peptides  al-
lows for determination of the time point, when angi-
ogenic activity begins, or the time point of the “angi-
ogenic  switch”.  The  RIPTag  model  is  a  transgenic 
mouse  model  of  carcinogenesis  and  angiogenesis 
where the oncogene SV40 T antigen is expressed un-
der the control of the rat insulin promoter [25]. Im-
munohistochemical  staining  of  pancreatic  sections 
with  a  monoclonal  antibody  against  the  murine  β3 
subunit indicated that αvβ3 is exclusively expressed 
on the vessels of the insulinoma and not on the tu-
mour  cells  themselves.  Autoradiographic  studies  of 
pancreatic sections of mice sacrificed 2 h after i.v. in-
jection of [125I]Gluco-RGD showed high focal activity 
accumulation  in  the  pancreas  in  RIP-Tag-positive 
mice. In contrast, for the RIP-Tag-negative mice only 
low  activity  accumulation  corresponding  to  the 
background was found. Moreover, there was a clear 
increase in activity accumulation in the pancreas of 
RIP-Tag-positive mice between 7 and 9 weeks, which 
corresponds with the tumour differentiation and the 
time point of the angiogenic switch. In contrast, for 
RIP-Tag-negative  mice,  tumour  accumulation  re-
mained  low  over  the  whole  observation  period.  In 
conclusion, these data suggest that αvβ3 expression 
can be quantified by radiolabelled RGD-peptides us-
ing static emission scans, and that αvβ3 expression on 
endothelial cells can be monitored sequentially during 
tumour-induced  angiogenesis  with  radiolabelled 
RGD-peptides.  
 However, lesion tracer uptake of many mono-
meric compounds can still be optimized because le-
sion  identification  is  difficult  in  areas  with  high 
physiological tracer uptake of monomeric RGD pep-
tides, such as liver, spleen and intestine. 
 Variations in tracer design are supposed to fur-
ther improve the performance of αvβ3 imaging, e.g. 
using multimeric RGD peptides. Since the interaction 
between  integrin  αvβ3  and  RGD-containing 
ECM-proteins involves multivalent binding sites with 
clustering  of  integrins,  the  concept  to  improve  the 
integrin αvβ3 binding affinity with multimeric cyclic 
RGD peptides could provide more effective antago-
nists with better targeting capability and higher cel-
lular  uptake  through  the  integrin-dependent  endo-
cytosis pathway [26,57,58]. A series of RGD peptides 
have been labelled with [18F] for PET imaging by Chen 
et al., using PEGylation and polyvalency to improve 
the  tumor-targeting  efficacy  and  pharmacokinetics. 
[18F]FB-E[c(RGDyK)]2  (abbreviated  as  [18F]FRGD2) 
showed  predominantly  renal  excretion  and  almost 
twice  as  much  tumor  uptake  in  the  same  animal 
model  compared  with  the  monomeric  tracer 
[18F]FB-c(RGDyK) [27-28]. Linear regression analysis 
of the dynamic microPET scans in six tumor xenograft 
models was carried out to correlate the tumor uptake 
with  integrin  αvβ3  expression  level  measured  by 
SDS-PAGE  autoradiography,  and  showed  an  excel-
lent correlation. Moreover, at late time points when 
most of the nonspecific binding had been cleared, the 
tumor/background  ratio  had  a  linear  relationship 
with  tumor  integrin  v3  expression.  This  demon-
strates that quantification of v3 expression is also 
feasible  with  static  emission  scans,  which  facilitates 
translation into the clinic. Multimeric RGD peptides 
have also been labeled with [64Cu] for PET imaging, 
using PEGylation and a multimeric approach to op-
timize the tumor-targeting efficacy and pharmacoki-
netics  [29-31].  The  tetrameric  RGD  peptide-based 
tracer, [64Cu]DOTA-E[E[c(RGDfK)]2]2, showed signif-
icantly higher receptor binding affinity than the cor-
responding monomeric and dimeric RGD analogues 
and demonstrated rapid blood clearance, high meta-
bolic stability, predominant renal excretion and sig-
nificant  receptor-mediated  tumor  uptake  with  good 
contrast  in  xenograft-bearing  mice  [32].  Therefore, 
[64Cu]DOTA-E[E[c(RGDfK)]2]2  is  a  promising  agent 
for peptide receptor radionuclide imaging as well as 
targeted  internal  radiotherapy  of  v3–positive  tu-
mors. A RGD octamer even further increased the in-
tegrin  avidity by  another  3-fold  compared  with  te-
tramer.  In  vivo  microPET  imaging  showed  that 
[64Cu]DOTA-RGD octamer had slightly higher initial 
tumor uptake  and  much  longer  tumor  retention  in 
U87MG  tumor  that  express  high  level  of  integrin. 
However, the octamer exhibited significantly higher 
tumor  uptake  in  mammary  adenocarcinoa-bearing 
c-neu oncomice that express medium level of integrin. 
The high renal uptake of the octamer in both subcu-
taneous U87MG xenografts and mammary adenocar-
cinoma–bearing  c-neu oncomice  compared  with  the 
tetramer was attributed mainly to the integrin posi-
tivity of the kidneys [33]. A systematic study on the 
influence of multimerisation on receptor affinity and 
tumour  uptake  was  carried  out  by  the  groups  of 
Wester  and  Kessler  who  synthesised  a  series  of 
monomeric, dimeric, tetrameric and octameric RGD 
peptides.  These  compounds  contain  different  num-
bers of c(RGDfE) peptides connected via PEG linker 
and  lysine  moieties,  which  are  used  as  branching 
units. They found an increasing binding affinity in the 
series monomer, dimer, tetramer and octamer in an in 
vitro binding assay, which was confirmed by small 
animal PET studies. Moreover, PET studies compar-
ing a tetrameric structure containing four c(RGDfE) 
peptides with a tetrameric compound containing only 




not  bind  to  the  αvβ3  integrin,  showed  a  threefold 
lower  activity  accumulation  in  the  tumour  for  the 
pseudo  monomeric  tetramer  than  for  the  “real”  te-
tramer,  indicating  that  the  higher  uptake  in  the  tu-
mour really is due to multimerisation and not based 
on  other  structural  effects  [34].  Furthermore  they 
could  demonstrate  that  moderate  metabolization  of 
multimeric constructs linked with L-Lys residues can 
improve tumor/background ratios when compared to 
analogues  linked  with  metabolically  stable  D-Lys 
residues. 
 Overall, the multimerisation approach leads to 
increased binding affinity and tumour uptake as well 
as retention and can improve the pharmacokinetics of 
peptide-based tracers. However, this does not neces-
sarily  has  to  relate  to  better  tumor-to-background 
contrast or improved clinical performance. A recent 
comparison  of  the  monomeric  compound 
[18F]Galacto-RGD and a dimeric RGD-peptide showed 
similar tumor-to-background contrast, despite higher 
absolute uptake of the dimeric compound in the tu-
mor [35]. Still, multimeric RGD peptides hold a lot of 
promise  for  future  clinical  use  and  first  results  of 
human studies are eagerly awaited. 
 Another strategy to image αvβ3 expression by 
PET is to use radiolabelled nanoparticles. In general, 
the  purpose  of  nanoparticle-based  radiotracers  for 
αvβ3 imaging is a little different from previously de-
scribed peptide- or antibody- based imaging. The fo-
cus of imaging with nanoparticle-based radiotracers is 
to provide guidance for integrin targeted drug deliv-
ery or therapy and not necessarily to evaluate receptor 
expression  levels.  Cai  et  al.  recently  developed  a 
QD-based probe for both NIRF and PET imaging [36]. 
QD surface modification with RGD peptides allows 
for  integrin  αvβ3  targeting  and  DOTA 
(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic 
acid; a very effective chelator for many metal ions) 
conjugation  enables  PET  imaging  after 
[64Cu]-labeling.  Using  this  dual-modality  probe,  it 
was found that the majority of the probe in the tumor 
was within the tumor vasculature.  
Another nanoparticle-approach is the use of sin-
gle-walled  carbon  nanotubes  (SWNTs).  SWNTs  ex-
hibit unique size, shape, and physical properties that 
make  them  promising  candidates  for  biological  ap-
plications [37-38]. Liu et al. recently investigated the 
biodistribution  of  [64Cu]-labeled  SWNTs  in  mice  by 
PET, biodistribution, and ex vivo Raman spectroscopy 
[39].  It  was found  that  properly  PEGylated  SWNTs 
have relatively long circulation half-life (a few hours) 
and  low  uptake  by  the  reticuloendothelial  system 
(RES).  Efficient  targeting  of  integrin  αvβ3-positive 
U87MG  tumor  in  mice  (~  15  %ID/g),  among  the 
highest of any nanoparticles ever reported, was also 
achieved with RGD peptide conjugated SWNTs. The 
unique  Raman  signatures  of  SWNTs  enabled  direct 
measurement of SWNTs in various mice tissue which 
confirmed  the  radionuclide-based  results.  Virtually 
no  kidney  uptake  was  observed  based  on  Raman 
measurement  of  the  tissue  homogenate,  although  a 
small fraction of [64Cu] detached from the SWNT did 
give  appreciable  kidney  uptake  in  PET  imaging. 
SWNTs  have  the  advantage  of  a  comparably  large 
surface area that can be potentially functionalized in a 
variety of ways to attach therapeutic agents and other 
moieties,  for  integrated  multimodality  imaging  and 
molecular therapy [36].  
Up to now, the radiotracer approach is still the 
only technique for imaging αvβ3 expression that has 
made the transition into the clinic. [18F]Galacto-RGD 
was the first PET tracer applied in patients and could 
successfully image αvβ3 expression in human tumors 
with good tumor/background ratios. In all patients, 
rapid,  predominantly  renal  tracer  elimination  was 
observed,  resulting  in  low  background  activity  in 
most  regions  of  the  body  [40].  High  inter-  and  in-
tra-individual variance in tracer accumulation in tu-
mor lesions was noted, suggesting substantial heter-
ogeneity of αvβ3 expression (Fig. 2). Further biodis-
tribution and dosimetry studies have confirmed rapid 
clearance  of  [18F]Galacto-RGD  from  the  blood  pool 
and primarily renal excretion. Background activity in 
lung and muscle tissue was low and the calculated 
effective dose found was approximately 19 μSv/MBq, 
which is very similar to an [18F]FDG scan [41]. There-
fore this tracer can be safely used in the clinic. Dis-
tribution volume (Dv) values, which are supposed to 
reflect the receptor concentration in the tissue, were 
on average four times higher for tumour tissue than 
for muscle tissue, suggesting specific tracer binding. 
In  a  recent  study,  dynamic  emission  scans  over  60 
minutes and kinetic modelling studies using the aorta 
as arterial input function were performed in patients 
with invasive ductal breast cancer. 





Figure 2: Two patients with sarcomas of the thigh (arrows). On the left side a patient with osteosarcoma of the right femur 
(A, B), on the right side a patient with a liposarcoma (C, D). In the MRI (A, C: T1w contrast enhanced, with fat suppression; 
transaxial) you see the large tumors with intense contrast enhancement. Despite the similar patterns of contrast en-
hancement, the corresponding [
18F]Galacto-RGD PET (B, D transaxial slices) shows quite different uptake patterns in both 
patients: in the osteosarcoma we see intense tracer uptake, predominantly in the tumor periphery, whereas in the lipo-
sarcoma there is mostly faint tracer uptake, with some focal areas of more intense tracer uptake. This suggests very het-
erogeneous v3 expression in these two tumors, despite intense contrast enhancement of both lesions. 
 
We compared SUVs derived from the last 9 time 
frames with the Dv values measured in normal tissue 
(breast,  muscle)  and  in  the  tumors.  The  correlation 
between both parameters increased continuously over 
time and was best at ~ 55 minutes p.i. with r = 0.92. 
This suggests that SUVs derived from static emission 
scans at ~ 60 min. p.i. can be used for assessment of 
αvβ3  receptor  density  with  reasonable  accuracy. 
Scans should not be started much earlier, as unspecific 
effects like tracer activity in the blood pool are likely 
to  affect  the  SUVs.  Finally,  in  another  study, 
[18F]Galacto-RGD  uptake  was  correlated  with  αvβ3 
expression as determined by immunohistochemistry. 
19 patients with solid tumours (musculoskeletal sys-
tem n = 10, melanoma n = 4, head and neck cancer n = 
2, glioblastoma n = 2, breast cancer n = 1) were ex-
amined with PET using [18]Galacto-RGD before sur-
gical  removal  of  the  lesions  [42].  SUVs  and  tu-
mour/blood  ratios  correlated  significantly  with  the 
intensity of immunohistochemical staining as well as 
with  the  microvessel  density.  Moreover,  immuno-
histochemistry confirmed lack of αvβ3 expression in 
normal tissue and in the two tumours without tracer 
uptake.  We  have  also  systematically  examined  dif-
ferent  tumor  entities  with  respect  to  their  v3  ex-
pression  patterns  with  [18F]Galacto-RGD  PET.  In 
squamous  cell  carcinoma  of  the  head  and  neck 
(SCCHN) we demonstrated good tumor/background 
ratios  with  [18F]Galacto-RGD  PET,  with  again  a 
widely varying intensity of tracer uptake. Immuno-




v3  expression,  suggesting  that  in  SCCHN, 
[18F]Galacto-RGD PET might be used as a surrogate 
parameter of angiogenesis [43]. In patients with glio-
blastoma, results were more complex. While normal 
brain tissue did not show significant tracer accumula-
tion (mean SUV, 0.09 +/- 0.04), GBMs demonstrated 
significant  but  heterogeneous  tracer  uptake,  with  a 
maximum in the highly proliferating and infiltrating 
areas  of  tumors  (mean  SUV,  1.6  +/-  0.5).  Immuno-
histochemical staining  was prominent in tumor mi-
crovessels  as  well  as  glial  tumor  cells.  In  areas  of 
highly  proliferating  glial  tumor  cells,  tracer  uptake 
(SUVs) in the PET images correlated with immuno-
histochemical  v3  integrin  expression  of  corre-
sponding tumor samples [44]. However, tracer uptake 
was  substantially  lower  as  compared  to  results  in 
tumors  outside the CNS.  As [18F]Galacto-RGD does 
not cross the intact blood-brain barrier, this might be 
an important factor influencing tracer uptake in CNS 
lesions.  Therefore  results  obtained  in  the  CNS  and 
outside the CNS probably have to be interpreted dif-
ferently. 
 We have also studied and compared the uptake 
patterns of [18F]FDG and [18F]Galacto-RGD in cancer 
patients  with  non  small  cell  lung  cancer  (NSCLC, 
n=10) and various other tumors (n=8). This compari-
son is interesting because in case of a close correlation 
of the two tracers, there would probably be no need 
for a specific tracer like [18F]Galacto-RGD. The results 
showed no correlation between the two tracers con-
cerning  all  lesions  (r  =  0.157).  For  the  subgroup  of 
[18F]FDG-avid  lesions  and  lesions  in  patients  with 
NSCLC,  there  was  a  slight  trend  towards  a  higher 
[18F]Galacto-RGD  uptake  in  more  [18F]FDG-avid  le-
sions (r = 0.337). However, the correlation coefficient 
was very low. Our results suggest that αvβ3 expres-
sion  and  glucose  metabolism  are  not  closely  corre-
lated  in  tumour  lesions  and  that  consequently 
[18F]FDG  cannot  provide  similar  information  as 
[18F]Galacto-RGD  [45].  Currently  we  are  correlating 
functional  imaging  of  angiogenesis  with  DCE-MRI 
and molecular imaging of αvβ3 expression and glu-
cose metabolism with [18F]Galacto-RGD and [18F]FDG 
in cancer patients. The combination of functional and 
molecular  imaging  holds  great  promise  for 
non-invasive  phenotyping  of  tumour  biology  and 
imaging of tissue heterogeneity in tumours. By dedi-
cated imaging software we defined regions with dif-
ferent  uptake  patterns  of  [18F]Galacto-RGD  and 
[18F]FDG: areas with both high [18F]Galacto-RGD and 
high [18F]FDG uptake (RGD+/FDG+), areas with ei-
ther high [18F]Galacto-RGD and low [18F]FDG uptake 
(RGD+/FDG-)  or  vice  versa  (RGD-/FDG+),  and  fi-
nally areas with both low [18F]Galacto-RGD and low 
[18F]FDG  uptake  (RGD-/FDG-).  In  areas  with  both 
low [18F]Galacto-RGD and low [18F]FDG uptake, pa-
rameters  of  tissue  perfusion  as  measured  by 
DCE-MRI  were  significantly  lower  as  compared  to 
areas  with  both  high  [18F]Galacto-RGD  and  high 
[18F]FDG uptake. However, in areas with either high 
[18F]Galacto-RGD  and  low  [18F]FDG  uptake  or  vice 
versa, there was a broad overlap of DCE-MRI results. 
Regarding different tumor regions, a significant cor-
relation between the initial area under the gadolinium 
concentration  time  curve  vs.  [18F]Galacto-RGD-PET 
(r=0.41;  p<0.05)  and  all  functional  MRI  parameters 
(IAUGC, regional blood flow and blood volume) vs. 
[18F]FDG-PET (r=0.37-0.54; p<0.05) could be demon-
strated, however, with only low to moderate correla-
tion coefficients
 [46]. These data suggest that in active 
tumor areas, perfusion, αvβ3 expression and glucose 
metabolism are largely independent variables of tu-
mor  biology.  In  summary  multimodality  functional 
and molecular imaging can provide complementary 
information and might help to evaluate tumor biology 
and angiogenesis in-vivo in its full complexity. 
 Despite the encouraging and promising results 
of  [18F]Galacto-RGD,  its  rather  complex  synthesis 
hampers its broad use in large clinical studies. How-
ever, besides academia, industry has also shown in-
terest in integrin imaging, which might facilitate PET 
imaging of integrin expression in large scale clinical 
trials,  and  maybe  one  day  even  in  clinical  routine. 
Recently, the SPECT tracer [99mTc]NC100692 was in-
troduced by GE healthcare for imaging αvβ3 expres-
sion  in  humans  and  was  first  evaluated  in  breast 
cancer by Bach-Gansmo et al. 19 of 22 tumors could be 
detected  with  this  agent,  which  was  safe  and  well 
tolerated by the patients [47]. Moreover, also a PET 
imaging agent was introduced, called [18F]fluciclatide 
(or formerly [18F]AH111585). In an animal model of 
Lewis  Lung  Cell  Cancer  (LLC),  PET  imaging  with 
[18F]AH111585 was able to visualize reduction of mi-
crovessel density during low dose paclitaxel therapy 
in an animal model, while uptake of [14C]FDG did not 
decrease [48]. This demonstrates that [18F]AH111585 
might be of potential value for assessment of response 
to  antiangiogenic  therapy.  First  studies  in  humans 
have demonstrated favourable biodistribution of this 
tracer  with  predominantly  renal  excretion.  Organs 
with highest radiation doses were the urinary bladder 
wall (0.124 mSv/MBq), the kidneys (0.102 mSv/MBq) 
and  the  cardiac  wall  (0.059  mSv/MBq).  The  mean 
effective dose was reported to be 0.026 mSv/MBq for 
3.5 h urinary bladder voiding intervals [49]. In 7 pa-
tients with metastasized breast cancer all 18 tumors 
detected by CT were visible on the [18F]AH111585 PET 





Figure 3: Example of multimodality multiparametric imaging of tumor biology in a patient with a metastasis of lung cancer 
to the right acetabulum (arrows). The [
18F]FDG PET/CT (A: PET; B: PET/CT) shows intense tracer uptake in the lesion. 
[
18F]Galacto-RGD PET (C: PET; D: PET/MRI image fusion) also shows intense tracer uptake, suggesting elevated v3 
expression in the lesion. Diffusion weighted MRI (E: b600 image, F: ADC map) shows restricted water diffusivity in the lesion 
as a potential marker of tumor cellularity. Finally DCE-MRI (G: subtraction image; H: contrast-enhanced T1w image) shows 
intense contrast enhancement of the lesion. 
 
 
 However, in the case of liver metastases, lesions 
were identified only indirectly as photopenic regions 
because  of  the  high  background  activity  in  normal 
liver  tissue.  Increased  uptake  compared  with  back-
ground (p = 0.002) was demonstrated in metastases in 
lung, pleura, bone, lymph node, and primary tumor 
[50].  The  authors  concluded  that  [18F]AH111585  is 
safe,  metabolically  stable,  and  able  to  detect  breast 
cancer lesions by PET in most anatomic sites.  
 Currently, a phase II study in up to 30 patients is 
being performed in patients with brain tumors, lung 
cancers,  SCCHN,  differentiated  thyroid  carcinoma, 
sarcoma  and  melanoma  to  correlate  dynamic  and 
static  [18F]AH111585  PET  imaging  with  histologic 
parameters  of  angiogenesis  (including  v3  expres-
sion)  and  DCE-CT  [51].  Based  on  these  promising 
results, it is expected that commercial agents for PET 
imaging of αvβ3 expression might be available in the 
not too distant future.  
4. PERSPECTIVE 
 PET  imaging  of  integrin  expression  has  suc-
cessfully made its way from bench to bedside. A va-
riety  of  PET  tracers  developed  by  the  academia  as 
well as the industry is currently being evaluated in 
clinical trials or in first dosimetry studies in patients 
[52]. Therefore a more widespread use of PET imag-
ing of integrin expression is expected in the near fu-
ture. In the next step, large clinical trials on the value 
of PET imaging of integrin expression for patient se-
lection  and  monitoring  in  the  context  of  antiangio-
genic or combined cytotoxic / antiangiogenic therapy 
will be necessary to define its ultimate potential clin-
ical value. In this respect, great promise lies in com-
bined MR-PET imaging, which one day might help to 
assess functional and molecular parameters of angi-
ogenesis in a one-stop-shop examination (Fig. 3). First 
prototypes for brain imaging have already been suc-
cessfully implemented, and sequential as well as fully 
integrated whole-body clinical MR-PET scanners have 
recently  been  installed  [53].  By  combined  MR-PET 
imaging, a complete assessment of the different as-
pects of tumour biology will hopefully become a real-
ity and will be implemented in therapy planning and 
response  evaluation  as  part  of  the  concept  of  “per-
sonalized medicine”. 
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